Actuate Therapeutics, Inc. Common stock
$0.98
-$0.01 (-1.41%)
$0.96Day Range$1.03
Key Statistics
Market Cap
$23.56M
Shares Outstanding
24.0M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Aug 13, 2024
Round Lot
100
Locale
US
Trading Data
Day Open
$1.00
Day High
$1.03
Day Low
$0.96
Volume
114.4K
VWAP
$0.99
Prev Close
$1.00
Transactions
--
Acc. Volume
--
About Actuate Therapeutics, Inc. Common stock
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.
PHARMACEUTICAL PREPARATIONSSIC 283412 employees1751 RIVER RUN, FORT WORTH, TX, 76107847-986-4190IPO Aug 13, 2024US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001652935
- Composite FIGI
- BBG00NK7LK03
- Share Class FIGI
- BBG00NK7LK12
- Ticker Root
- ACTU
- SIC Code
- 2834
About Actuate Therapeutics, Inc. Common stock (ACTU) Stock
Actuate Therapeutics, Inc. Common stock (ACTU) closed the 2026-09-18 session at $0.98, down 1.41% versus the previous close (-0.01). The stock opened at $1.00 and traded between $0.96 and $1.03 during that session. Session trading volume was 114K shares. The volume-weighted average price (VWAP) is $0.99.
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.
Actuate Therapeutics, Inc. Common stock has a market capitalization of $23.6 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. ACTU is listed on the XNAS exchange. The company employs approximately 12 people. Actuate Therapeutics, Inc. Common stock is headquartered in FORT WORTH, TX. The recorded listing date is 2024-08-13.
On this page you can find market ACTU stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.